Eslicarbazepine: A Comprehensive Monograph on its Pharmacology, Clinical Application, and Safety Profile

1.0 Executive Summary

Eslicarbazepine is a third-generation antiepileptic drug (AED) belonging to the dibenzazepine carboxamide class, representing a significant pharmacological refinement of its predecessors, carbamazepine and oxcarbazepine.[1] It is indicated for the treatment of partial-onset seizures, both as monotherapy and as an adjunctive therapy, in adults and children aged four years and older.[4] The therapeutic rationale for Eslicarbazepine is rooted in its unique mechanism of action and favorable pharmacokinetic profile. Its primary pharmacodynamic effect is the stabilization of the inactive state of voltage-gated sodium channels (VGSCs), with a notable and selective affinity for the slow-inactivated state.[6] This state-dependent action allows for targeted inhibition of the rapid, repetitive neuronal firing characteristic of an epileptic focus, while minimizing interference with normal physiological neuronal activity, potentially contributing to its efficacy and tolerability.

Clinically, Eslicarbazepine is administered as a prodrug, eslicarbazepine acetate, which undergoes rapid and extensive first-pass hydrolysis to its single active metabolite, eslicarbazepine, also known as S-licarbazepine.[2] This metabolic pathway is a key advantage, as it avoids the formation of the potentially toxic epoxide metabolites associated with carbamazepine and the racemic mixture of active metabolites produced by oxcarbazepine.[2] The resulting pharmacokinetic profile is predictable and linear, with a long elimination half-life that supports a convenient once-daily dosing regimen, a factor that can significantly enhance patient adherence in the long-term management of epilepsy.[10]

The efficacy of Eslicarbazepine has been robustly established in a comprehensive clinical trial program, demonstrating significant reductions in seizure frequency as both an add-on therapy and as a monotherapy, including in patients newly diagnosed with epilepsy.[3] While generally well-tolerated, its safety profile is characterized by common, dose-related central nervous system (CNS) adverse effects, including dizziness, somnolence, headache, and nausea.[4] Clinicians must also remain vigilant for rare but serious adverse reactions, such as severe dermatologic events (e.g., Stevens-Johnson Syndrome), hyponatremia, and an increased risk of suicidal ideation, which is a class warning for all AEDs.[5] Overall, Eslicarbazepine offers a therapeutic profile comparable in efficacy to older dibenzazepines but with potential advantages in tolerability, drug-interaction potential, and dosing convenience, positioning it as a valuable and versatile option in the modern epileptology armamentarium.

2.0 Chemical Identity and Physicochemical Properties

A precise understanding of the chemical and physical identity of a pharmaceutical agent is fundamental to its study and clinical application. This section provides a comprehensive characterization of Eslicarbazepine, including its nomenclature, structural features, and key physicochemical properties.

2.1 Nomenclature and Identifiers

To ensure unambiguous identification across scientific literature, regulatory filings, and clinical databases, Eslicarbazepine is cataloged under numerous names and identifiers.

The primary non-proprietary name for the active moiety is Eslicarbazepine.[16] Its systematic chemical names, which describe its molecular structure according to IUPAC and other conventions, include

(5S)-5-hydroxy-5,6-dihydrobenzo[b]benzazepine-11-carboxamide and (10S)-10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide.[6]

Throughout its development and in research contexts, it has been referred to by various synonyms and codes, including (S)-Licarbazepine, S(+)-Liscarbazepine, (S)-MHD, and the developmental codes BIA 2-194 and CGP-13751.[6]

The compound is registered in major chemical and pharmacological databases under specific identifiers, which are consolidated in Table 2.1. These identifiers are crucial for accurate data retrieval and cross-referencing.

2.2 Structural Analysis and Stereochemistry

The therapeutic properties of Eslicarbazepine are intrinsically linked to its specific three-dimensional structure and stereochemistry.

Its molecular formula is C15​H14​N2​O2​, corresponding to an average molecular weight of approximately 254.29 g/mol and a monoisotopic mass of approximately 254.1055 g/mol.[16] The molecule's structure is defined by a dibenz[b,f]azepine nucleus with a carboxamide group at the 5-position and a hydroxyl group at the 10-position. This structure can be represented by the SMILES string

C1[C@@H](C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N)O and is uniquely identified by the InChIKey BMPDWHIDQYTSHX-AWEZNQCLSA-N.[6]

The most critical aspect of its structure is its stereochemistry. The carbon atom at the 10-position is a chiral center, meaning the molecule exists as two non-superimposable mirror images, or enantiomers. Eslicarbazepine is specifically the (S)-enantiomer of the compound known as licarbazepine.[1] This stereochemical purity is not a trivial detail but is the central tenet of its development. Its predecessor, oxcarbazepine, is metabolized in the body to a racemic mixture containing both the (S)-enantiomer and the (R)-enantiomer of licarbazepine in a ratio of approximately 4-5 to 1.[2] The development of eslicarbazepine acetate as a prodrug for the single (S)-enantiomer was a deliberate strategy in rational drug design. This approach, often termed a "chiral switch," was predicated on the hypothesis that the S-enantiomer possessed the majority of the desired anticonvulsant activity and might offer a more favorable tolerability profile compared to the R-enantiomer or the racemic mixture.[3] Therefore, the chemical identity of Eslicarbazepine as a single, specific enantiomer is the foundation of its therapeutic rationale, aiming to provide a more refined and predictable pharmacological agent than its predecessors.

2.3 Physical and Chemical Properties

The physical properties of Eslicarbazepine are relevant for its formulation, handling, and laboratory analysis. In its solid state, it appears as a white to pale yellow or off-white crystalline solid.[21] It has a defined melting point in the range of 188-190°C and a predicted boiling point of

431.3±55.0 °C.[21]

Its solubility profile indicates that it is soluble in dimethyl sulfoxide (DMSO) and slightly soluble in other organic solvents such as chloroform, methanol, and pyridine.[6] Analysis of its properties against Lipinski's Rule of Five—a set of criteria used to evaluate a compound's potential for oral bioavailability—shows no violations. With two hydrogen bond donors and four hydrogen bond acceptors, it aligns with the characteristics of a drug likely to be well-absorbed orally.[17]

For research and long-term stability, the compound should be stored in a freezer at -20°C, protected from light and moisture.[19] The formulated medicinal product, however, is stable when stored in a closed container at room temperature, away from direct heat, light, and moisture.[4]

Table 2.1: Chemical and Regulatory Identifiers for Eslicarbazepine

This table consolidates the key identifiers for Eslicarbazepine, providing a quick-reference guide for researchers, clinicians, and regulatory professionals. This structured format enhances the report's utility as a practical reference document, ensuring accuracy when cross-referencing the compound across various databases.

Identifier Type	Value	Source Snippet(s)
CAS Number	104746-04-5	16
DrugBank ID	DB14575	16
IUPAC Name	(5S)-5-hydroxy-5,6-dihydrobenzo[b]benzazepine-11-carboxamide	17
Molecular Formula	C15​H14​N2​O2​	16
Average Molecular Weight	~254.29 g/mol	16
FDA UNII	S5VXA428R4	18
ATC Code	N03AF04	18
InChIKey	BMPDWHIDQYTSHX-AWEZNQCLSA-N	6
SMILES	C1C@@HO

3.0 Pharmacodynamics and Mechanism of Action

The anticonvulsant effects of Eslicarbazepine are derived from its specific interactions at the molecular level within the central nervous system. Its mechanism of action is a refinement of the activity seen in other dibenzazepine carboxamides, offering a more targeted approach to neuronal stabilization.

3.1 Primary Mechanism: Stabilization of Voltage-Gated Sodium Channels

The principal mechanism of action of Eslicarbazepine is the inhibition of voltage-gated sodium channels (VGSCs). These ion channels are fundamental to neuronal function, as they are responsible for the rapid influx of sodium ions that underlies the rising phase of an action potential. In epilepsy, certain populations of neurons become hyperexcitable, leading to the rapid, repetitive, and disorganized electrical discharges that manifest as seizures.

Eslicarbazepine exerts its therapeutic effect by binding to VGSCs and stabilizing them in the inactivated state. Following an action potential, VGSCs briefly enter this inactivated state, during which they are refractory to further stimulation. By prolonging this state, Eslicarbazepine effectively reduces the number of channels available to open in response to a subsequent depolarizing stimulus. This action dampens the ability of neurons to sustain high-frequency firing, thereby interrupting the pathological activity of a seizure focus and producing the overall physiologic effect of "Decreased Central Nervous System Disorganized Electrical Activity".

3.2 Comparative Analysis of Channel State Affinity

A key pharmacodynamic feature that distinguishes Eslicarbazepine from its predecessors is its preferential affinity for a specific conformational state of the VGSC. In vitro electrophysiological studies have demonstrated that Eslicarbazepine has a particularly high affinity for the slow-inactivated state of the channel, a mechanism that differs from the action of carbamazepine, which primarily alters fast inactivation.

This state-dependent selectivity has significant clinical implications. VGSCs can enter a slow-inactivated state during prolonged periods of depolarization or sustained, high-frequency firing—the exact conditions that occur within an epileptic focus. By preferentially targeting this state, Eslicarbazepine acts as a more targeted inhibitor. It exerts its maximal inhibitory effect precisely on the pathologically hyperexcitable neurons responsible for seizure generation, while having a lesser impact on neurons firing at normal physiological rates. This targeted action provides a plausible molecular basis for its robust efficacy and may contribute to an improved tolerability profile compared to agents with less state-dependent selectivity. The drug is, in effect, more active when and where it is most needed, a hallmark of a refined therapeutic agent.

3.3 Secondary and Ancillary Mechanisms

While VGSC blockade is the well-established primary mechanism, other actions may contribute to the overall therapeutic profile of Eslicarbazepine. By stabilizing neuronal membranes through its primary action on sodium channels, Eslicarbazepine may indirectly reduce the excessive presynaptic release of glutamate, the brain's primary excitatory neurotransmitter. Since excessive glutamate release is a key factor in seizure propagation and excitotoxicity, this downstream effect could further contribute to its anticonvulsant and neuroprotective properties. Additionally, in vitro binding studies have shown that Eslicarbazepine competitively interacts with the neurotoxin site 2 of the VGSC, providing further detail on its molecular binding site. However, the stabilization of the slow-inactivated state of the VGSC remains the core and most clinically relevant mechanism of action.

4.0 Comprehensive Pharmacokinetic Profile

The pharmacokinetic profile of a drug—its absorption, distribution, metabolism, and excretion (ADME)—determines its dosing regimen, potential for drug interactions, and overall clinical utility. Eslicarbazepine possesses a favorable pharmacokinetic profile characterized by its efficient prodrug conversion, predictable linear kinetics, and a long half-life that allows for convenient once-daily dosing.

4.1 Absorption and Bioavailability

Eslicarbazepine is administered orally in the form of its prodrug, eslicarbazepine acetate. This formulation is extensively absorbed from the gastrointestinal tract, with studies indicating at least 90% absorption. A key clinical advantage is that its absorption is not significantly affected by the presence of food, which allows patients to take the medication without regard to meals, increasing convenience and likely improving adherence.

Following oral administration, eslicarbazepine acetate is rapidly and extensively converted to its active metabolite, eslicarbazepine. Peak plasma concentrations (Tmax​) of this active moiety are typically reached within 1 to 4 hours. The bioavailability of eslicarbazepine following administration of the acetate prodrug is high and has been reported to be approximately 16% greater than that achieved after an equivalent dose of oxcarbazepine, another prodrug that yields the same active metabolite.

4.2 Distribution and Protein Binding

Once in the systemic circulation, eslicarbazepine is distributed throughout the body. It exhibits a low degree of binding to plasma proteins, with the bound fraction being less than 40%. Furthermore, this binding is independent of the drug's concentration within the therapeutic range.

This low level of protein binding is a clinically advantageous feature. Only the unbound, or free, fraction of a drug is pharmacologically active and available to be metabolized and excreted. Drugs with high protein binding (typically >90%) are susceptible to displacement interactions; if a second highly protein-bound drug is co-administered, it can displace the first from its binding sites, causing a sudden and potentially toxic increase in the free concentration. Because eslicarbazepine has low protein binding, the risk of such displacement interactions is minimal. This contributes to its predictable pharmacokinetic profile and makes it a safer option in the context of polypharmacy, which is common in the management of epilepsy.

4.3 Metabolism: The Prodrug-to-Active Metabolite Pathway

The metabolism of eslicarbazepine acetate is a defining feature that distinguishes it from its predecessors. It is a prodrug designed for one purpose: efficient delivery of the single, active S-enantiomer of licarbazepine.

Upon absorption, eslicarbazepine acetate undergoes rapid and nearly complete first-pass metabolism via hydrolysis, primarily mediated by esterase enzymes in the liver. This conversion is so efficient that the parent prodrug, eslicarbazepine acetate, is generally undetectable in plasma. The resulting active metabolite, eslicarbazepine (S-licarbazepine), is responsible for virtually all of the drug's pharmacological activity and accounts for approximately 92% of the total systemic exposure.

This metabolic pathway offers two critical advantages over related drugs. First, unlike carbamazepine, it avoids metabolism through the cytochrome P450 system to form the carbamazepine-10,11-epoxide, a reactive metabolite implicated in both therapeutic effects and significant toxicity. Second, unlike oxcarbazepine, which is metabolized to a racemic mixture of S-licarbazepine and R-licarbazepine, eslicarbazepine acetate is converted almost exclusively to the S-enantiomer, with minimal (<5%) chiral conversion to the R-enantiomer. This "cleaner" metabolic profile, yielding a single active species, contributes to more predictable and less variable pharmacokinetics.

Regarding its own influence on drug-metabolizing enzymes, Eslicarbazepine has a minimal effect on the cytochrome P450 (CYP) system. It is considered a moderate inhibitor of CYP2C19 and a weak inducer of CYP3A4 and UDP-glucuronosyltransferase (UGT) enzymes. Importantly, it does not induce its own metabolism (autoinduction), a phenomenon that complicates the dosing of carbamazepine.

4.4 Excretion and Elimination

The elimination of eslicarbazepine and its metabolites from the body occurs predominantly through the kidneys. Over 90% of an administered dose is recovered in the urine, indicating that renal excretion is the primary clearance pathway. The main chemical species found in the urine are unchanged eslicarbazepine (approximately two-thirds of the excreted amount) and its inactive glucuronide conjugate, eslicarbazepine glucuronide (approximately one-third). Other minor metabolites, such as R-licarbazepine and oxcarbazepine, account for only a very small percentage of the excreted drug.

Eslicarbazepine has a long biological half-life (t1/2​), reported to be in the range of 10-20 hours in some studies and 20-24 hours in others. This prolonged half-life is the pharmacokinetic basis for its convenient once-daily dosing regimen. Following the initiation of treatment, steady-state plasma concentrations are achieved after 4 to 5 days of consistent daily administration. Within the approved therapeutic dose range of 400 mg to 1600 mg, the pharmacokinetics are linear and dose-proportional, meaning that a doubling of the dose results in a doubling of the plasma concentration, which simplifies dose adjustments.

4.5 Pharmacokinetics in Special Populations

The pharmacokinetic properties of Eslicarbazepine can be altered in certain patient populations, necessitating dosage adjustments.

• Renal Impairment: Given that the drug is primarily cleared by the kidneys, renal function is the most critical factor affecting its pharmacokinetics. In patients with moderate to severe renal impairment, defined as a creatinine clearance (CLcr​) of less than 50 mL/minute, the elimination of eslicarbazepine is significantly slowed. To avoid drug accumulation and potential toxicity, the dosage in these patients should be reduced by approximately 50% across the initial, titration, and maintenance phases. No adjustment is necessary for mild renal impairment.
• Hepatic Impairment: Eslicarbazepine is well-tolerated in patients with mild to moderate hepatic impairment, and no dosage adjustments are required. Studies have shown that while first-pass hydrolysis of the prodrug may be slightly decreased, this does not meaningfully alter the systemic exposure to the active metabolite, eslicarbazepine. The use of Eslicarbazepine in patients with severe hepatic impairment has not been studied and is therefore not recommended.
• Age, Gender, and Race: Clinical studies have found no clinically significant differences in the pharmacokinetics of Eslicarbazepine based on gender or race. While age itself does not necessitate a dose adjustment, caution is advised in geriatric patients, as they are more likely to have an age-related decline in renal function that would require dose modification based on their creatinine clearance.

Table 4.1: Summary of Key Pharmacokinetic Parameters of Eslicarbazepine

This table links the core pharmacokinetic data of eslicarbazepine to its direct clinical relevance, providing a powerful educational and reference tool. This format bridges the gap between basic pharmacology and clinical practice, allowing the reader to quickly grasp why the pharmacokinetic properties of Eslicarbazepine are considered favorable for the management of epilepsy.

Parameter	Value	Clinical Implication	Source Snippet(s)
Bioavailability	High (>90%)	Ensures reliable and consistent drug exposure with oral administration.
Tmax​ (Peak Time)	1–4 hours	Rapid attainment of therapeutic concentrations after dosing.
Protein Binding	<40%	Low potential for drug-drug interactions due to displacement from plasma proteins.
Half-life (t1/2​)	10–24 hours	Long half-life supports a convenient once-daily dosing regimen, improving patient adherence.
Primary Elimination Route	Renal (>90%)	Dosage must be adjusted in patients with moderate-to-severe renal impairment.
Key Active Metabolite	Eslicarbazepine (S-licarbazepine)	Prodrug design delivers a single active enantiomer, leading to predictable effects.
Effect of Food	None	Dosing flexibility; can be taken with or without meals, enhancing convenience.

5.0 Clinical Efficacy in the Management of Partial-Onset Seizures

The clinical utility of Eslicarbazepine is supported by a robust body of evidence from a comprehensive program of clinical trials. These studies have established its efficacy across a range of clinical scenarios in patients with partial-onset seizures.

5.1 Approved Indication

Based on extensive clinical data, eslicarbazepine acetate is officially indicated for the treatment of partial-onset seizures (also referred to as focal seizures), with or without secondary generalization. This approval extends to both adult and pediatric patients aged four years and older. It can be used either as a monotherapy for newly diagnosed patients or as an adjunctive (add-on) treatment for patients whose seizures are not adequately controlled by other antiepileptic drugs.

5.2 Efficacy as Adjunctive Therapy

The initial approval and foundational evidence for Eslicarbazepine were established through several large, randomized, double-blind, placebo-controlled Phase III trials. These pivotal studies enrolled adult patients with refractory partial-onset seizures, meaning their seizures were not controlled despite treatment with one or two other AEDs. The results consistently demonstrated that adjunctive therapy with Eslicarbazepine, at once-daily doses of 800 mg and 1200 mg, was statistically superior to placebo in reducing seizure frequency. The efficacy was further supported by long-term extension studies, which showed sustained seizure control over time.

The clinical development program was strategically designed to validate the drug's efficacy and safety not just as a niche product, but as a versatile therapeutic option. The progression from adjunctive to monotherapy and then to pediatric use demonstrates a comprehensive validation of its utility. This pathway establishes the drug as a versatile, front-line option in the epileptologist's armamentarium. Furthermore, subgroup analyses and dedicated studies have shown that this efficacy extends to specific populations, including elderly patients and those who had previously failed to respond to treatment with carbamazepine, highlighting its utility even within its own drug class.

5.3 Efficacy as Monotherapy

Following its success as an adjunctive therapy, Eslicarbazepine was also investigated and approved for use as a monotherapy. This is a critical indication, as it positions the drug as a viable option for initial treatment in newly diagnosed patients or as a replacement therapy for patients wishing to simplify their regimen. The approval for monotherapy was largely based on a pivotal, double-blind, non-inferiority trial that compared once-daily Eslicarbazepine to the established standard of care, twice-daily controlled-release carbamazepine, in patients with newly diagnosed partial-onset seizures. The study successfully demonstrated that Eslicarbazepine was non-inferior to carbamazepine in terms of seizure freedom rates. The efficacy was maintained during a subsequent two-year open-label extension phase, confirming its long-term effectiveness as a single agent.

5.4 Use in Pediatric Populations

The therapeutic indication for Eslicarbazepine was expanded to include children aged 4 to 17 years, following the successful completion of studies demonstrating its efficacy and acceptable safety profile in this population. As is standard for pediatric AEDs, the dosing in this age group is not fixed but is instead based on body weight to ensure appropriate exposure levels across different developmental stages. This expansion significantly broadens the clinical utility of Eslicarbazepine, making it an option for a wide age range of patients with focal epilepsy.

6.0 Dosage, Administration, and Therapeutic Management

The effective and safe use of Eslicarbazepine requires a thorough understanding of its recommended dosing, administration methods, and strategies for treatment initiation and discontinuation. The dosing regimen is tailored based on age, body weight, and renal function.

6.1 Recommended Dosing for Adult Patients

For adult patients, treatment with eslicarbazepine acetate follows a structured titration schedule to optimize tolerability.

• Initial Dose: The standard recommended starting dosage is 400 mg administered orally once daily. This initial low dose helps the patient acclimatize to the medication.
• Aggressive Start: In specific clinical situations where a more rapid onset of seizure control is deemed to outweigh the increased risk of adverse reactions, treatment may be initiated at a higher dose of 800 mg once daily.
• Titration: After one week at the initial dose, the dosage should be increased. The recommended titration involves weekly increments of 400 mg to 600 mg, guided by the patient's clinical response and tolerability.
• Maintenance Dose: The typical maintenance dosage range for adults is 800 mg to 1600 mg once daily. For patients on monotherapy, an 800 mg daily dose may be sufficient, particularly if the 1200 mg dose is not well tolerated. For patients on adjunctive therapy who do not achieve a satisfactory response with a 1200 mg daily dose, the dose may be increased to the maximum of 1600 mg daily.

6.2 Weight-Based Dosing for Pediatric Patients (4 to 17 Years)

In the pediatric population, the dosing of eslicarbazepine acetate is carefully calculated based on body weight to ensure appropriate drug exposure. The regimen is administered once daily. The specific dosing guidelines are summarized in Table 6.1. Titration to the maintenance dose should be done gradually, with increases occurring no more frequently than once per week, and the titration increments should not exceed the initial starting dose for that weight band.

Table 6.1: Pediatric Dosing Guidelines by Body Weight

This table is clinically essential for safe and effective prescribing in the pediatric population. It synthesizes complex dosing information from multiple sources into a single, clear, and easy-to-use reference format, thereby reducing the risk of dosing errors.

Data compiled from sources.

6.3 Administration Guidelines and Patient Counseling

Proper administration is key to achieving the desired therapeutic effect.

• Administration: Eslicarbazepine acetate should be taken once daily. It can be administered with or without food, offering flexibility to the patient. Patients should be counseled to take their dose at approximately the same time each day to help maintain stable blood levels of the medication.
• Dosage Forms: The medication is available as oral tablets in strengths of 200 mg, 400 mg, 600 mg, and 800 mg. For patients who have difficulty swallowing pills, the tablets may be crushed and mixed with a small amount of soft food (like applesauce) or water immediately prior to administration.
• Missed Dose: Patients should be instructed to take a missed dose as soon as they remember. However, if it is close to the time for their next scheduled dose, they should skip the missed dose and resume their regular schedule. It is important to emphasize that they should not take a double dose to make up for a missed one, as this can increase the risk of side effects. Missing doses can increase the risk of breakthrough seizures.

6.4 Protocol for Treatment Initiation, Titration, and Discontinuation

The management of Eslicarbazepine therapy requires careful attention to initiation, dose adjustment, and cessation.

• Initiation and Titration: The recommended slow, weekly titration schedule is a critical component of the treatment protocol. This gradual increase in dosage is designed to enhance tolerability, particularly for the common CNS-related adverse effects like dizziness and somnolence, which are most likely to occur during the initial phase of treatment.
• Discontinuation: As with all AEDs, abrupt discontinuation of Eslicarbazepine should be strictly avoided. Suddenly stopping the medication can lower the seizure threshold and precipitate an increase in seizure frequency or even status epilepticus, a medical emergency. When treatment is to be stopped, the dosage should be tapered down gradually over a period of weeks under the supervision of a healthcare provider.

7.0 Safety Profile and Adverse Drug Reactions

A comprehensive assessment of a drug's safety and tolerability is essential for its appropriate clinical use. While Eslicarbazepine is generally well-tolerated, it is associated with a range of potential adverse effects, from common, manageable side effects to rare, but serious, life-threatening reactions.

7.1 Common and Dose-Related Adverse Reactions

The most frequently encountered adverse drug reactions (ADRs) associated with Eslicarbazepine therapy are primarily related to the central nervous system and are often dose-dependent.

• Very Common (affecting >1 in 10 people): The most prevalent side effects reported in clinical trials include dizziness (up to 28%), somnolence or sleepiness (up to 18%), headache (up to 15%), and nausea (up to 16%).
• Common (affecting up to 1 in 10 people): Other common ADRs include visual disturbances such as blurred vision and diplopia (double vision), vertigo (a sensation of spinning), vomiting, diarrhea, fatigue, tremor, ataxia (impaired coordination), and balance disorders. Skin rash and hyponatremia (low sodium levels) are also classified as common.

Many of these effects, particularly dizziness and somnolence, are most prominent during the initial titration period and may lessen as the body adapts to the medication. Their incidence and severity are often related to the dose, as demonstrated in pooled clinical trial data (see Table 7.1).

7.2 Serious Warnings and Precautions

Beyond the common side effects, Eslicarbazepine carries warnings for several rare but potentially severe adverse reactions that require immediate medical attention and careful patient monitoring.

7.2.1 Dermatologic Reactions and Pharmacogenomic Considerations

Eslicarbazepine is associated with a risk of serious and potentially life-threatening cutaneous adverse reactions. These include Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). SJS and TEN are severe mucocutaneous reactions characterized by widespread blistering and sloughing of the skin, while DRESS is a multi-organ hypersensitivity reaction. Patients must be educated to immediately report any signs of these reactions, such as a developing rash, blistering, peeling skin, fever, or painful sores in the mouth, eyes, or genital area.

A critical consideration is the pharmacogenomic link to these reactions. Due to its structural similarity to carbamazepine, there is a theoretical increased risk of SJS/TEN in individuals carrying specific human leukocyte antigen (HLA) alleles. The HLA-B*1502 allele, found predominantly in individuals of Asian descent, is strongly associated with carbamazepine-induced SJS/TEN. The HLA-A*3101 allele, more common in European and Japanese populations, is associated with a broader range of hypersensitivity reactions, including DRESS. While the direct risk with Eslicarbazepine is less quantified, caution and consideration of genetic screening may be warranted in at-risk populations before initiating therapy.

7.2.2 Hyponatremia

Treatment with Eslicarbazepine can lead to a reduction in serum sodium levels, a condition known as hyponatremia. While often asymptomatic, if sodium levels fall significantly, it can cause symptoms such as nausea, fatigue, confusion, irritability, muscle weakness or cramps, and, paradoxically, a worsening of seizures. Therefore, it is recommended to monitor serum sodium levels periodically, especially in patients with pre-existing risk factors such as underlying renal disease, the elderly, or those on concomitant medications known to lower sodium levels (e.g., diuretics, carbamazepine).

7.2.3 Suicidal Behavior and Ideation

In common with all antiepileptic drugs, Eslicarbazepine carries a class-wide warning regarding an increased risk of suicidal thoughts and behavior. Pooled analyses of AED trials have shown this risk to be approximately 1 in 500 patients. Patients, their families, and caregivers must be counseled to be vigilant for the emergence or worsening of depression, anxiety, agitation, hostility, or any unusual changes in mood or behavior, as well as the emergence of suicidal ideation or self-harming behaviors. Any such changes should be reported to the healthcare provider immediately.

7.2.4 Neurological and Cognitive Effects

The common CNS side effects of dizziness and somnolence can be significant enough to impact daily functioning. Eslicarbazepine can also cause disturbances in gait, balance, and coordination, as well as cognitive dysfunction (e.g., difficulty concentrating, memory impairment) and visual changes. Due to these potential effects, patients should be explicitly cautioned against driving, operating heavy machinery, or engaging in other potentially hazardous activities until they have a clear understanding of how the medication affects them.

7.2.5 Other Serious Reactions

• Drug-Induced Liver Injury: Although rare, cases of clinically apparent liver injury have been reported. The product label recommends discontinuing the drug in patients who develop jaundice or other evidence of significant hepatic dysfunction.
• Hematologic Reactions: Rare but serious blood disorders, including agranulocytosis (a severe lack of white blood cells), leukopenia, and pancytopenia, have been reported. Discontinuation should be considered if evidence of these conditions appears.
• Anaphylaxis and Angioedema: Life-threatening hypersensitivity reactions, including anaphylaxis and angioedema (swelling of the face, lips, and throat), can occur. These are medical emergencies and require immediate discontinuation of the drug and appropriate intervention.

7.3 Management of Adverse Effects

Many of the common, dose-related CNS side effects can be mitigated by adhering to a slow dose titration schedule upon initiation of therapy. If adverse effects persist at the target dose, a dose reduction may be considered. Upon discontinuation of the drug for any reason, a gradual taper is essential to minimize the risk of withdrawal-related seizures.

Table 7.1: Incidence of Common Adverse Reactions in Adjunctive Therapy Trials (vs. Placebo)

This table provides high-quality, evidence-based data from pooled, placebo-controlled clinical trials, quantifying the risk of the most common adverse effects. It clearly demonstrates the dose-response relationship for many of these events, which is invaluable information for clinical decision-making and patient counseling.

Data adapted from source.

8.0 Clinically Significant Drug Interactions

The potential for drug-drug interactions is a critical consideration in the management of epilepsy, where polypharmacy is common. The interaction profile of Eslicarbazepine is a direct consequence of its metabolic pathway. While it offers advantages over older dibenzazepines, it is not metabolically inert and requires careful management.

8.1 Interactions with Other Antiepileptic Drugs (AEDs)

Interactions with other AEDs are among the most clinically relevant for Eslicarbazepine.

• Oxcarbazepine: Concurrent use of eslicarbazepine acetate and oxcarbazepine is contraindicated and must be avoided. Both are prodrugs that are metabolized to the same active species, licarbazepine. Co-administration would lead to excessive and unpredictable levels of the active metabolite, significantly increasing the risk of dose-related toxicity.
• Carbamazepine: Co-administration is possible but requires caution. Clinical studies have shown that this combination can lead to a higher incidence of adverse effects, specifically diplopia, impaired coordination, and dizziness. Furthermore, the interaction is bidirectional: carbamazepine is a potent enzyme inducer and can reduce the plasma concentrations of eslicarbazepine, potentially compromising its efficacy. Dose adjustments of either or both drugs may be necessary based on clinical response and tolerability.
• Enzyme-Inducing AEDs (Phenytoin, Phenobarbital, Primidone): Similar to carbamazepine, these potent enzyme-inducing AEDs can accelerate the metabolism of eslicarbazepine, leading to lower plasma levels. Consequently, patients taking these concomitant medications may require higher doses of Eslicarbazepine to achieve the desired therapeutic effect.
• Phenytoin: The interaction with phenytoin is also bidirectional and complex. While phenytoin induces eslicarbazepine metabolism, Eslicarbazepine is a moderate inhibitor of CYP2C19, the primary enzyme that metabolizes phenytoin. This can lead to an increase in phenytoin serum concentrations, potentially to toxic levels. Therefore, careful monitoring of phenytoin levels and potential dose reduction of phenytoin may be required when Eslicarbazepine is added.

8.2 Impact on Cytochrome P450 and UGT Enzymes

Eslicarbazepine's own effects on the major drug-metabolizing enzyme systems are modest but clinically significant.

• CYP3A4 Induction: Eslicarbazepine is a weak inducer of the CYP3A4 enzyme. This can accelerate the metabolism and thereby reduce the plasma levels and efficacy of other drugs that are substrates of CYP3A4. The most critical example of this interaction is with hormonal contraceptives. Eslicarbazepine can decrease the effectiveness of oral contraceptives containing levonorgestrel and ethinylestradiol. Women of childbearing potential using hormonal contraception must be counseled on this interaction and advised to use an additional, effective non-hormonal (barrier) method of birth control during treatment.
• CYP2C19 Inhibition: Eslicarbazepine is a moderate inhibitor of the CYP2C19 enzyme. This can slow the metabolism and increase the plasma concentrations of drugs that are substrates of CYP2C19. As noted above, the most prominent example is phenytoin, but this could also affect other drugs like clopidogrel (interfering with its activation) or certain antidepressants.

8.3 Interactions with CNS Depressants

Due to its primary effects on the central nervous system, Eslicarbazepine can have additive effects when combined with other CNS depressant substances.

• Alcohol (Ethanol): The concomitant use of alcohol with Eslicarbazepine should be avoided or limited. This combination can potentiate CNS side effects such as dizziness, drowsiness, confusion, difficulty concentrating, and impairment of judgment and motor coordination.
• Other CNS Depressants: Caution is warranted when Eslicarbazepine is co-administered with other medications that cause CNS depression, including benzodiazepines, opioids, tricyclic antidepressants, and certain antihistamines. The additive sedative effects can increase the risk of falls and other accidents.

9.0 Comparative Analysis: Eslicarbazepine in the Context of Dibenzazepines

Eslicarbazepine did not emerge in a vacuum; it is the culmination of a decades-long, rational drug design strategy aimed at optimizing the dibenzazepine pharmacophore for the treatment of epilepsy. A direct comparison with its predecessors, carbamazepine (first generation) and oxcarbazepine (second generation), illuminates its specific advantages and its place in therapy. This evolutionary progression from a "crude" but effective molecule (carbamazepine) to a highly refined, single-enantiomer agent (eslicarbazepine) demonstrates a clear trend in pharmaceutical development towards maximizing safety and predictability by optimizing metabolism and pharmacokinetics.

9.1 Structural and Metabolic Distinctions

The core differences between the three generations of dibenzazepines lie in their metabolism, which directly influences their safety and interaction profiles.

• Carbamazepine (1st Generation): This foundational drug is metabolized extensively by the CYP3A4 enzyme to a reactive 10,11-epoxide metabolite. This epoxide is pharmacologically active and contributes to both the anticonvulsant effect and significant dose-related toxicity. Furthermore, carbamazepine is a potent inducer of multiple hepatic enzymes, including its own metabolism (a process known as autoinduction). This leads to complex, time-dependent pharmacokinetics and a high potential for numerous drug-drug interactions.
• Oxcarbazepine (2nd Generation): Developed specifically to improve upon carbamazepine, oxcarbazepine is a prodrug that is rapidly reduced to its active metabolite, licarbazepine, thereby avoiding the problematic epoxide pathway. However, this metabolic process yields a racemic mixture of (S)-licarbazepine and (R)-licarbazepine. While a less potent enzyme inducer than carbamazepine, it still possesses significant interaction potential.
• Eslicarbazepine Acetate (3rd Generation): This agent represents the final refinement in this lineage. It is a prodrug designed to deliver only the active (S)-enantiomer, eslicarbazepine (S-licarbazepine), via hydrolysis. This highly specific metabolic pathway avoids both the epoxide metabolite of carbamazepine and the generation of the R-enantiomer seen with oxcarbazepine. This results in the most refined metabolic profile of the class, with the lowest potential for enzyme induction and the most predictable pharmacokinetics.

9.2 Comparative Efficacy and Tolerability

• Efficacy: All three drugs share the same primary mechanism of action—blockade of voltage-gated sodium channels—and are considered highly effective for the treatment of partial-onset seizures. The therapeutic value of Eslicarbazepine is not based on superior efficacy but on an optimized profile. This was confirmed in a head-to-head clinical trial which demonstrated that once-daily Eslicarbazepine was non-inferior in efficacy to twice-daily controlled-release carbamazepine in newly diagnosed patients.
• Tolerability: The refined metabolism of Eslicarbazepine is theorized to translate into an improved tolerability profile. By avoiding the toxic epoxide and the R-enantiomer, and by providing more stable plasma concentrations due to its long half-life and lack of autoinduction, it may be associated with a lower burden of CNS side effects for some patients. However, the overall types of adverse effects observed—such as dizziness, somnolence, hyponatremia, and the risk of serious rash—are qualitatively similar across the entire class, reflecting their shared pharmacophore.

9.3 Pharmacokinetic Advantages and Clinical Implications

The most significant clinical advantages of Eslicarbazepine over its predecessors stem directly from its superior pharmacokinetic properties.

• Dosing Simplicity: Eslicarbazepine's long elimination half-life and lack of autoinduction permit a simple, convenient once-daily dosing regimen. This stands in stark contrast to carbamazepine, which typically requires multiple daily doses and complex dose adjustments during the initial weeks of therapy to account for autoinduction. This simplicity can greatly enhance patient adherence, a critical factor in achieving long-term seizure control.
• Pharmacokinetic Predictability: The pharmacokinetics of Eslicarbazepine are linear, meaning that plasma concentrations are directly proportional to the administered dose. This makes dose adjustments straightforward and the therapeutic response more predictable. This contrasts with the non-linear and time-varying kinetics of carbamazepine, which can make therapeutic drug monitoring and dose optimization more challenging.

In summary, Eslicarbazepine's primary value proposition is not novel efficacy, but rather optimized delivery and a more predictable, "cleaner" pharmacological profile that offers tangible benefits in clinical practice through improved convenience, adherence, and potentially, tolerability.

10.0 Regulatory Status and Developmental Timeline

The journey of Eslicarbazepine from laboratory discovery to global clinical use reflects a structured and strategic development process aimed at establishing its role in modern epilepsy treatment.

• Development: Eslicarbazepine acetate was originally developed by the Portuguese pharmaceutical company Bial, marking a significant contribution from the European pharmaceutical sector.
• European Approval: The drug first received regulatory approval in the European Union in April 2009. Bial partnered with the Japanese company Eisai for marketing in Europe, where it is available under the trade names Zebinix® and Exalief®.
• United States Approval: In the United States, the drug is marketed by Sunovion Pharmaceuticals under the brand name Aptiom®. The regulatory timeline in the U.S. proceeded in a stepwise fashion:
• The New Drug Application (NDA) was first submitted to the U.S. Food and Drug Administration (FDA) in March 2009.
• Initial FDA approval was granted on November 8, 2013, for its use as an adjunctive therapy for partial-onset seizures in adults.
• The indication was expanded to include monotherapy for adults on August 28, 2015.
• A further expansion to include pediatric patients (ages 4 years and older) was approved on September 14, 2017, solidifying its role across a broad age spectrum.
• Australian Approval: In Australia, the drug was approved by the Therapeutic Goods Administration (TGA) on May 10, 2021, and is marketed as Zebinix®. Upon its approval, it was included in the Black Triangle Scheme, a program for new medicines that requires additional post-market safety monitoring to gather more real-world data.

11.0 Emerging Research and Potential Off-Label Applications

While firmly established for epilepsy, the mechanism of action of Eslicarbazepine suggests potential utility in other neurological conditions characterized by neuronal hyperexcitability. Research into these off-label applications is ongoing, with varying levels of evidence. The differential success observed in these areas highlights the nuances of translating a specific molecular mechanism across different disease pathologies.

11.1 Trigeminal Neuralgia (TN)

• Rationale: Trigeminal neuralgia is a debilitating neuropathic pain condition characterized by severe, paroxysmal, electric shock-like facial pain. Its pathophysiology is believed to involve ectopic, high-frequency discharges in the trigeminal nerve, a mechanism highly analogous to that of a focal seizure. The established first-line treatments for TN are carbamazepine and oxcarbazepine, which act by suppressing these aberrant neuronal discharges. Given its identical primary mechanism of action and potentially more favorable profile, Eslicarbazepine is a logical candidate for this indication.
• Evidence: While large-scale randomized controlled trials are still lacking, a growing body of evidence from smaller, open-label, and retrospective studies suggests significant efficacy. One key multicenter study of 18 patients, many of whom were refractory to previous treatments, reported a high responder rate of 88.9%. In this study, treatment with Eslicarbazepine led to a statistically significant reduction in both the intensity (median visual analogue scale score dropping from 9.5 to 2.5) and the frequency (median weekly episodes dropping from 70 to 0.37) of pain attacks. Notably, 44.4% of patients became completely asymptomatic.
• Clinical Status: At present, the evidence is considered insufficient to recommend Eslicarbazepine as a first-line treatment for TN. However, it is rapidly emerging as a promising and well-tolerated second- or third-line option for patients who experience inadequate pain relief or intolerable side effects with carbamazepine or oxcarbazepine. Its potential advantages, including simpler dosing and fewer drug interactions, make it an attractive alternative in this often difficult-to-treat population.

11.2 Bipolar Disorder

• Rationale: The therapeutic use of anticonvulsants as mood stabilizers is well-established, with carbamazepine and oxcarbazepine having demonstrated efficacy, particularly in the management of acute mania. The rationale for investigating Eslicarbazepine in bipolar disorder stems from this class effect and the hypothesis that its refined profile might offer benefits.
• Evidence: The evidence base for Eslicarbazepine in bipolar disorder is significantly weaker and more equivocal than for trigeminal neuralgia. The available data consists primarily of isolated case reports describing its successful use in patients with refractory mania who were intolerant to other mood stabilizers. However, these anecdotal successes have not been consistently replicated in controlled settings. A 2015 assessment failed to show a statistically significant difference from placebo for this indication. Phase 2 clinical trials have been completed to investigate the efficacy of eslicarbazepine acetate in acute manic episodes and for recurrence prevention in Bipolar I Disorder, but the results have not been compelling enough to lead to regulatory approval or widespread clinical adoption.
• Clinical Status: The efficacy of Eslicarbazepine in bipolar disorder remains largely unproven and its role is unknown. It is not currently a recommended treatment. The disparity in evidence between TN and bipolar disorder is instructive. It suggests that the therapeutic utility of a highly targeted VGSC blocker like Eslicarbazepine is likely highest in disorders directly and primarily driven by focal neuronal hyperexcitability (like epilepsy and TN). Its potential in more complex neuropsychiatric disorders like bipolar disorder, which involve widespread changes in multiple neurotransmitter systems and intracellular signaling pathways, is far less certain and would require more substantial and convincing evidence.

12.0 Conclusion: Expert Synthesis and Clinical Perspective

Eslicarbazepine stands as a successful example of incremental innovation and rational drug design within the field of epileptology. It is not a revolutionary agent with a novel mechanism of action, but rather a deliberate and clinically meaningful optimization of the well-established dibenzazepine carboxamide class. Its development represents a logical progression aimed at enhancing the safety, tolerability, and convenience of a proven therapeutic approach.

The primary contribution of Eslicarbazepine to the treatment of partial-onset seizures lies in its refined pharmacological profile. By designing a prodrug that delivers a single, active enantiomer (S-licarbazepine), its metabolism avoids the reactive epoxide intermediate of carbamazepine and the racemic mixture of oxcarbazepine. This "cleaner" metabolic pathway results in predictable, linear pharmacokinetics and a long elimination half-life. These characteristics are not merely academic; they translate directly into tangible clinical benefits, most notably a simple and convenient once-daily dosing regimen. In the context of a chronic illness like epilepsy, where long-term adherence is paramount to successful outcomes, this simplification of the treatment regimen is a significant advantage.

While its efficacy is comparable to that of older agents like carbamazepine, the optimized pharmacokinetic and metabolic profile may lead to improved tolerability and a more predictable dose-response relationship for some patients. However, it is crucial to recognize that Eslicarbazepine shares the same class-related safety concerns as its predecessors. Diligent clinical vigilance and patient education are essential for managing the risks of serious dermatologic reactions, hyponatremia, and suicidal ideation. The potential for pharmacogenomic screening for HLA alleles in at-risk populations before initiating therapy should be considered to mitigate the risk of severe cutaneous reactions.

In conclusion, Eslicarbazepine has firmly earned its place as a versatile and valuable therapeutic option in the management of partial-onset seizures in both adults and children. It offers clinicians a more predictable and convenient alternative to older dibenzazepines, embodying the progress of pharmaceutical science in refining existing therapies to improve patient care. Furthermore, emerging evidence for its use in trigeminal neuralgia is promising and warrants further investigation through larger, well-controlled clinical trials to formally establish its role in this and other related neuropathic pain conditions.

Works cited

1. Eslicarbazepine Monograph for Professionals - Drugs.com, accessed September 28, 2025, https://www.drugs.com/monograph/eslicarbazepine.html
2. A Review of Eslicarbazepine Acetate for the Adjunctive Treatment of ..., accessed September 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3663619/
3. Eslicarbazepine Acetate: A Well-Kept Secret? - PMC, accessed September 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2812714/
4. Eslicarbazepine (oral route) - Side effects & dosage - Mayo Clinic, accessed September 28, 2025, https://www.mayoclinic.org/drugs-supplements/eslicarbazepine-oral-route/description/drg-20084844
5. Eslicarbazepine: Package Insert / Prescribing Information - Drugs.com, accessed September 28, 2025, https://www.drugs.com/pro/eslicarbazepine.html
6. Eslicarbazepine (BIA 2-194, CGP 13751, (S)-Licarbazepine, CAS Number: 104746-04-5), accessed September 28, 2025, https://www.caymanchem.com/product/35008/eslicarbazepine
7. What is the mechanism of Eslicarbazepine Acetate? - Patsnap Synapse, accessed September 28, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-eslicarbazepine-acetate
8. Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies - PMC, accessed September 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5336540/
9. en.wikipedia.org, accessed September 28, 2025, https://en.wikipedia.org/wiki/Eslicarbazepine_acetate
10. Eslicarbazepine acetate: A therapeutic agent of paramount importance in acute anticonvulsant therapy, accessed September 28, 2025, https://oaji.net/pdf.html?n=2017/3064-1514423997.pdf
11. Pharmacokinetics of eslicarbazepine acetate in ... - ResearchGate, accessed September 28, 2025, https://www.researchgate.net/publication/5691094_Pharmacokinetics_of_eslicarbazepine_acetate_in_patients_with_moderate_hepatic_impairment
12. Eslicarbazepine acetate – Knowledge and References - Taylor & Francis, accessed September 28, 2025, https://taylorandfrancis.com/knowledge/Medicine_and_healthcare/Pharmaceutical_medicine/Eslicarbazepine_acetate/
13. Eslicarbazepine Side Effects: Common, Severe, Long Term - Drugs.com, accessed September 28, 2025, https://www.drugs.com/sfx/eslicarbazepine-side-effects.html
14. Eslicarbazepine (Aptiom): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing, accessed September 28, 2025, https://www.webmd.com/drugs/2/drug-165805/aptiom-oral/details
15. Eslicarbazepine Acetate (Aptiom) - Epilepsy Medication, accessed September 28, 2025, https://www.cureepilepsy.org/understanding-epilepsy/treatments/epilepsy-medications/eslicarbazepine-acetate/
16. Eslicarbazepine: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 28, 2025, https://go.drugbank.com/drugs/DB14575
17. eslicarbazepine | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed September 28, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7350
18. Eslicarbazepine | C15H14N2O2 | CID 9881504 - PubChem, accessed September 28, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Eslicarbazepine
19. Eslicarbazepine | CAS#104746-04-5 | antiepileptic drug - MedKoo Biosciences, accessed September 28, 2025, https://www.medkoo.com/products/16992
20. Eslicarbazepine | 104746-04-5 | Metabolites - Shimadzu Chemistry & Diagnostics, accessed September 28, 2025, https://www.schd-shimadzu.com/en/metabolites/3017-169191-Eslicarbazepine.html
21. Eslicarbazepine | 104746-04-5 - ChemicalBook, accessed September 28, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB9500846.htm
22. www.ncbi.nlm.nih.gov, accessed September 28, 2025, https://www.ncbi.nlm.nih.gov/books/NBK548939/#:~:text=Its%20mechanism%20of%20action%20is,that%20is%20characteristic%20of%20epilepsy.
23. Full article: Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures - Taylor & Francis Online, accessed September 28, 2025, https://www.tandfonline.com/doi/full/10.2147/TCRM.s6382
24. Zebinix | Therapeutic Goods Administration (TGA), accessed September 28, 2025, https://www.tga.gov.au/resources/auspmd/zebinix
25. Eslicarbazepine Acetate - Epilepsy Foundation, accessed September 28, 2025, https://www.epilepsy.com/tools-resources/seizure-medication-list/eslicarbazepine-acetate
26. The pharmacokinetic, safety, and tolerability profiles of eslicarbazepine acetate are comparable between Korean and White subjects, accessed September 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9468563/
27. Eslicarbazepine acetate: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 28, 2025, https://go.drugbank.com/drugs/DB09119
28. APTIOM® (eslicarbazepine acetate) tablets, for oral use - accessdata.fda.gov, accessed September 28, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022416s000lbl.pdf
29. Eslicarbazepine Completed Phase 3 Trials for Epilepsy With Simple or Complex Partial Onset Seizures Treatment - DrugBank, accessed September 28, 2025, https://go.drugbank.com/drugs/DB14575/clinical_trials?conditions=DBCOND0043459&phase=3&purpose=treatment&status=completed
30. Attachment: Product Information for Eslicarbazepine acetate, accessed September 28, 2025, https://www.tga.gov.au/sites/default/files/auspar-eslicarbazepine-acetate_-210909-pi.pdf
31. Aptiom (eslicarbazepine acetate) FDA Approval History - Drugs.com, accessed September 28, 2025, https://www.drugs.com/history/aptiom.html
32. Eslicarbazepine Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed September 28, 2025, https://www.drugs.com/dosage/eslicarbazepine.html
33. Aptiom Dosage Guide - Drugs.com, accessed September 28, 2025, https://www.drugs.com/dosage/aptiom.html
34. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ESLICARBAZEPINE ACETATE - APOTEX, accessed September 28, 2025, https://www.apotex.com/products/us/downloads/pre/esli_imtb_ins.pdf
35. Aptiom dosage: Form, strengths, how to take, and more - Healthline, accessed September 28, 2025, https://www.healthline.com/health/drugs/aptiom-dosage
36. Zebinix | European Medicines Agency (EMA) - Europa.eu, accessed September 28, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/zebinix
37. www.cureepilepsy.org, accessed September 28, 2025, [https://www.cureepilepsy.org/understanding-epilepsy/treatments/epilepsy-medications/eslicarbazepine-acetate/#:~:text=The%20most%20common%20side%20effects,%2C%20stuffy%20nose%2C%20infections%20(including](https://www.google.com/url?q=https://www.cureepilepsy.org/understanding-epilepsy/treatments/epilepsy-medications/eslicarbazepine-acetate/%23:~:text%3DThe%2520most%2520common%2520side%2520effects,%252C%2520stuffy%2520nose%252C%2520infections%2520(including&sa=D&source=editors&ust=1759047112527729&usg=AOvVaw0r-r6zXUxM18kXV7GW5zin)
38. Information for the user Zebinix 200 mg tablets Eslicarbazepine acetate Read all of this leaflet carefully befo, accessed September 28, 2025, https://www.medicines.org.uk/emc/files/pil.4460.pdf
39. Information for the user Zebinix 50 mg/ml oral suspension Eslicarbazepine acetate Read all of this leaflet car, accessed September 28, 2025, https://www.medicines.org.uk/emc/files/pil.9732.pdf
40. Eslicarbazepine and Alcohol/Food Interactions - Drugs.com, accessed September 28, 2025, https://www.drugs.com/food-interactions/eslicarbazepine.html
41. Eslicarbazepine - LiverTox - NCBI Bookshelf, accessed September 28, 2025, https://www.ncbi.nlm.nih.gov/books/NBK548939/
42. What are the side effects of Eslicarbazepine Acetate? - Patsnap Synapse, accessed September 28, 2025, https://synapse.patsnap.com/article/what-are-the-side-effects-of-eslicarbazepine-acetate
43. Eslicarbazepine acetate for trigeminal neuralgia | Neurología (English Edition) - Elsevier, accessed September 28, 2025, https://www.elsevier.es/en-revista-neurologia-english-edition--495-articulo-eslicarbazepine-acetate-for-trigeminal-neuralgia-S217358082030208X
44. What is the role of APTIOM (eslicarbazepine) in the treatment of Trigeminal Neuralgia?, accessed September 28, 2025, https://www.droracle.ai/articles/62387/aptiom-for-trigeminal-neuraliga
45. Therapeutic Approach for Trigeminal Neuralgia: A Systematic Review - MDPI, accessed September 28, 2025, https://www.mdpi.com/2227-9059/11/10/2606
46. Assessment of efficacy and safety of eslicarbazepine acetate for the treatment of trigeminal neuralgia - PubMed, accessed September 28, 2025, https://pubmed.ncbi.nlm.nih.gov/29369456/
47. Eslicarbazepine acetate, an alternative for patients with trigeminal neuralgia with hyponatremia induced by carbamazepine or oxcarbazepine - ResearchGate, accessed September 28, 2025, https://www.researchgate.net/publication/385879540_Eslicarbazepine_acetate_an_alternative_for_patients_with_trigeminal_neuralgia_with_hyponatremia_induced_by_carbamazepine_or_oxcarbazepine
48. Eslicarbazepine Acetate in the Management of Refractory Bipolar Disorder - ResearchGate, accessed September 28, 2025, https://www.researchgate.net/publication/233418136_Eslicarbazepine_Acetate_in_the_Management_of_Refractory_Bipolar_Disorder
49. Eslicarbazepine acetate – an unexplored therapeutic option in the treatment of bipolar disorders - ResearchGate, accessed September 28, 2025, https://www.researchgate.net/publication/366571736_Eslicarbazepine_acetate_-_an_unexplored_therapeutic_option_in_the_treatment_of_bipolar_disorders
50. Eslicarbazepine acetate in the management of refractory bipolar disorder - PubMed, accessed September 28, 2025, https://pubmed.ncbi.nlm.nih.gov/23151469/
51. Eslicarbazepine acetate Completed Phase 2 Trials for Bipolar 1 Disorder Treatment, accessed September 28, 2025, https://go.drugbank.com/drugs/DB09119/clinical_trials?conditions=DBCOND0020745&phase=2&purpose=treatment&status=completed